Nicole Pezous

2.2k total citations · 1 hit paper
20 papers, 1.5k citations indexed

About

Nicole Pezous is a scholar working on Pharmacology, Molecular Biology and Surgery. According to data from OpenAlex, Nicole Pezous has authored 20 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 5 papers in Molecular Biology and 3 papers in Surgery. Recurrent topics in Nicole Pezous's work include Cholinesterase and Neurodegenerative Diseases (3 papers), Sphingolipid Metabolism and Signaling (3 papers) and Treatment of Major Depression (3 papers). Nicole Pezous is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (3 papers), Sphingolipid Metabolism and Signaling (3 papers) and Treatment of Major Depression (3 papers). Nicole Pezous collaborates with scholars based in Switzerland, United States and Germany. Nicole Pezous's co-authors include Marc Vandemeulebroecke, Simon Travis, Peter Higgins, Walter Reinisch, Gerard Bruin, Steve Lewitzky, Arthur P. Bertolino, Marco Londei, Stephan Bek and Marek Karczewski and has published in prestigious journals such as Annals of Neurology, Gut and Science Translational Medicine.

In The Last Decade

Nicole Pezous

20 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

2012 1.2k citations Wolfgang Hueber, Bruce E. Sands et al. Gut profile →

Peers

Nicole Pezous

IMMUN

GENET

RHEUM

EPIDE

Andrew P. R. Sutherland Australia

Martin Raithel Germany

Ayşen Karaduman Türkiye

Xiaohong Huang United States

Dmitry V. Ostanin United States

Thao Nguyen Australia

Stephanie S. Weinreich Netherlands

Hongmei Li United States

Nicolas Borot France

Gabriela Gorelik Argentina

Andrew P. R. Sutherland Australia

Nicole Pezous

946 ×1.2

IMMUN

298 ×0.7

GENET

357 ×1.4

188 ×0.8

RHEUM

241 ×1.1

EPIDE

Citations per year, relative to Nicole Pezous Nicole Pezous (= 1×) peers Andrew P. R. Sutherland

Countries citing papers authored by Nicole Pezous

Since Specialization

Citations

This map shows the geographic impact of Nicole Pezous's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicole Pezous with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicole Pezous more than expected).

Fields of papers citing papers by Nicole Pezous

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicole Pezous. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicole Pezous. The network helps show where Nicole Pezous may publish in the future.

Co-authorship network of co-authors of Nicole Pezous

This figure shows the co-authorship network connecting the top 25 collaborators of Nicole Pezous. A scholar is included among the top collaborators of Nicole Pezous based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicole Pezous. Nicole Pezous is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gomez‐Mancilla, Baltazar, Kenneth M. Dürsteler, Marc Vogel, et al.. (2025). Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial. Science Translational Medicine. 17(792). eadi4505–eadi4505. 2 indexed citations

Espay, Alberto J., Luca Marsili, Abhimanyu Mahajan, et al.. (2020). Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. Annals of Neurology. 89(1). 91–98. 20 indexed citations

Vormfelde, Stefan Viktor, Nicole Pezous, Gilbert Lefèvre, et al.. (2020). A Pooled Analysis of Three Randomized Phase I/IIa Clinical Trials Confirms Absence of a Clinically Relevant Effect on the QTc Interval by Umibecestat. Clinical and Translational Science. 13(6). 1316–1326. 6 indexed citations

Graf, Ana, Carine Kolly, Valérie Dubost, et al.. (2019). FTS3‐01‐01: UMIBECESTAT (CNP520) IS NOT ASSOCIATED WITH CHANGES IN HIPPOCAMPAL MORPHOLOGY IN RATS OR CHANGES IN CSF AD BIOMARKERS IN HUMANS TREATED FOR 3 MONTHS. Alzheimer s & Dementia. 15(7S_Part_17). 2 indexed citations

David, Olivier, Nicole Pezous, Michael Lang, et al.. (2017). Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod. Clinical Pharmacology in Drug Development. 7(2). 217–221. 4 indexed citations

Ufer, Mike, Marie‐Laure Rouzade‐Dominguez, Gunilla Huledal, et al.. (2017). [P1–051]: RESULTS FROM A 3‐MONTH STUDY IN HEALTHY SUBJECTS AGED 60 YEARS WITH THE BACE INHIBITOR CNP520. Alzheimer s & Dementia. 13(7S_Part_5). 1 indexed citations

Rouzade‐Dominguez, Marie‐Laure, Nicole Pezous, Olivier J. David, et al.. (2017). The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease. Neurogastroenterology & Motility. 29(8). 8 indexed citations

Barch, Deanna M., Stephen R. Marder, Michael P. Harms, et al.. (2016). Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 71. 66–75. 9 indexed citations

Legangneux, Eric, Kasra Shakeri‐Nejad, Vassilios Aslanis, et al.. (2016). Cardiac Effects of Siponimod (BAF312) Re-initiation After Variable Periods of Drug Discontinuation in Healthy Subjects. Clinical Therapeutics. 38(3). 631–645.e1. 8 indexed citations

10.

Ufer, Mike, Marie‐Laure Rouzade‐Dominguez, Gunilla Huledal, et al.. (2016). O1‐10‐06: Results From a First‐in‐Human Study with the Bace Inhibitor CNP520. Alzheimer s & Dementia. 12(7S_Part_4). 9 indexed citations

11.

Shakeri‐Nejad, Kasra, Vassilios Aslanis, Louise Mooney, et al.. (2015). Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects. Clinical Therapeutics. 37(11). 2489–2505.e2. 13 indexed citations

12.

Reilmann, Ralf, Marie‐Laure Rouzade‐Dominguez, Carsten Saft, et al.. (2015). A randomized, placebo‐controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Movement Disorders. 30(3). 427–431. 64 indexed citations

13.

Feuerbach, Dominik, Nicole Pezous, H. Weiss, et al.. (2014). AQW051, a novel, potent and selectiveα7 nicotinicAChreceptor partial agonist: pharmacological characterization and phaseIevaluation. British Journal of Pharmacology. 172(5). 1292–1304. 27 indexed citations

14.

Gomez‐Mancilla, Baltazar, Ronald Brand, Tim Jürgens, et al.. (2013). Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia. 34(2). 103–113. 35 indexed citations

15.

Hueber, Wolfgang, Bruce E. Sands, Steve Lewitzky, et al.. (2012). Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 61(12). 1693–1700. 1156 indexed citations breakdown →

16.

Schaefer, Franz, Mieczysław Litwin, Jacek Zachwieja, et al.. (2011). Efficacy and safety of valsartan compared to enalapril in hypertensive children. Journal of Hypertension. 29(12). 2484–2490. 37 indexed citations

17.

Branco, Jaime, et al.. (2008). P.8.a.014 Milnacipran for the treatment of fibromyalgia syndrome: a european multicenter, double-blind, placebo-controlled trial. European Neuropsychopharmacology. 18. S574–S575. 12 indexed citations

18.

Sechter, D., et al.. (2004). A comparative study of milnacipran and paroxetine in outpatients with major depression. Journal of Affective Disorders. 83(2-3). 233–236. 38 indexed citations

19.

Rouillon, F., Blake M. Warner, Nicole Pezous, & J.C. Bisserbe. (2000). Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study. International Clinical Psychopharmacology. 15(3). 133–140. 31 indexed citations

20.

Tignol, Jean-Pierre, et al.. (1998). Double‐blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major dipressive episode. Acta Psychiatrica Scandinavica. 97(2). 157–165. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact